Physician payments from industry are associated with greater medicare Part D prescribing costs

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Perlis, Roy H ^a   Perlis, Clifford S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEMALE; FUNDING; GENERAL SURGERY; GEOGRAPHIC ORIGIN; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; LOWEST INCOME GROUP; MALE; MEDICAL FEE; MEDICARE; NEUROLOGY; PATIENT CARE; PHYSICIAN INCOME; SEX DIFFERENCE; COST; DRUG COST; DRUG INDUSTRY; ECONOMICS; MEDICINE; PHYSICIAN; PRESCRIPTION; UNITED STATES;

COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICARE PART D; MEDICINE; PHYSICIANS; UNITED STATES;

EID: 84969699834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155474     Document Type: Article

References (21)

1. Field MJ, Lo B. Conflict of Interest in Medical Research, Education, and Practice: National Acadamies Press; 2009.
2. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. New England Journal of Medicine. 2007; 356(17):1742-50. PMID: 17460228
3. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. Jama. 2003; 290(2):252-5. PMID: 12851281
4. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? Jama. 2000; 283 (3):373-80. PMID: 10647801
5. Spurling G, Mansfield P, Montgomery B, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010; 7(10):e1000352. doi: 10.1371/journal.pmed.1000352 PMID: 20976098
6. Alkhaled L, Kahale L, Nass H, Brax H, Fadlallah R, Badr K, et al. Legislative, educational, policy and other interventions targeting physicians' interaction with pharmaceutical companies: a systematic review. BMJ open. 2014; 4(7).
7. Provider Payment Sunshine Act 114th Cong. (2016).
8. Compilation of the Social Security Laws: Transparency Reports and Reporting of Physician Ownership or Investment Interests: Social Security Administration; 2013 [cited 2016 February 1, 2016]. Available from: https://www.ssa.gov/OP-Home/ssact/title11/1128G.htm.
9. NPPES Data Dissemination 2015. Available from: http://download.cms.gov/nppes/NPI-Files.html.
10. Coster D. Constrasts. Encyclopedia of Biostatistics2015.
11. Searle SR. Linear Models for Unbalanced Data: Wiley; 2006. 536 p.
12. Austin PC, Hoch JS. Estimating linear regression models in the presence of a censored independent variable. Stat Med. 2004; 23(3):411-29. PMID: 14748036
13. Hoadley J, Cubanski J, Neuman T. Section 1: Part D Enrollment and Plan Availability: The Henry J. Kaiser Family Foundation; 2015 [April 28, 2016]. Available from: http://kff.org/report-section/medicarepart-d-at-ten-years-section-1-part-d-enrollment-and-plan-availability/.
14. Talking With Your Doctor About Pharmaceutical Company Payments: Pro Publica; 2015. Available from: https://projects.propublica.org/docdollars/howtouse.
15. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ. Patients' views on financial conflicts of interest in cancer research trials. New England Journal of Medicine. 2006; 355(22):2330-7. PMID: 17135586
16. Loewenstein G, Sah S, Cain DM. The Unintended Consequences of Conflict of Interest Disclosure. Jama. 2012; 307(7):669-70. doi: 10.1001/jama.2012.154 PMID: 22337676
17. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: Pervasive effects of disclosing conflicts of interest. The Journal of Legal Studies. 2005; 34(1):1-25.
18. Gagnon M, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5(1):e1. doi: 10.1371/journal.pmed.0050001 PMID: 18177202
19. Physician Financial Transparency Reports (Sunshine Act) American Medical Association2016 [cited 2016 February 1]. Available from: http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-actand-physician-financial-transparency-reports.page?].
20. Santhakumar S, Adashi EY. The Physician Payment Sunshine Act: testing the Value of Transparency. Jama. 2015; 313(1):23-4. doi: 10.1001/jama.2014.15472 PMID: 25473969
21. Boccuti C, Swoope C, Damico A, Neuman T. Medicare patients' access to physicians: a synthesis of the evidence: Kaiser Family Foundation; 2013 [cited 2016 February 10, 2016]. Available from: http:// kff.org/medicare/issue-brief/medicarepatients-access-to-physicians-asynthesis-of-the-evidence/.